QuantRx Biomedical Corporation (QTXB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2022 | - USD | -100.0% |
| 2021 | 2.63 Million USD | 8.95% |
| 2020 | 2.42 Million USD | 9.84% |
| 2019 | 2.2 Million USD | 9.82% |
| 2018 | 2 Million USD | 3.12% |
| 2017 | 1.94 Million USD | 14.85% |
| 2016 | 1.69 Million USD | 25.35% |
| 2015 | 1.35 Million USD | 12.59% |
| 2014 | 1.2 Million USD | 53.36% |
| 2013 | 782.69 Thousand USD | 69.58% |
| 2012 | 461.54 Thousand USD | 117.57% |
| 2011 | 212.14 Thousand USD | 382.14% |
| 2010 | 44 Thousand USD | 0.0% |
| 2009 | 44 Thousand USD | -98.89% |
| 2008 | 3.97 Million USD | 363.86% |
| 2007 | 856.09 Thousand USD | 0.0% |
| 2006 | - USD | -100.0% |
| 2005 | 55.4 Thousand USD | -87.76% |
| 2004 | 452.5 Thousand USD | 0.0% |
| 2003 | 452.5 Thousand USD | 0.0% |
| 2002 | 452.5 Thousand USD | 13.13% |
| 2001 | 400 Thousand USD | -2.44% |
| 2000 | 410 Thousand USD | -16.33% |
| 1999 | 490 Thousand USD | 6.52% |
| 1998 | 460 Thousand USD | -4.17% |
| 1997 | 480 Thousand USD | 29.73% |
| 1996 | 370 Thousand USD | 0.0% |
| 1995 | - USD | -100.0% |
| 1994 | 2 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q1 | 2.69 Million USD | 2.04% |
| 2022 Q2 | 2.68 Million USD | -0.31% |
| 2022 FY | - USD | -100.0% |
| 2022 Q4 | - USD | -100.0% |
| 2022 Q3 | 2.82 Million USD | 5.48% |
| 2021 Q1 | 2.47 Million USD | 2.23% |
| 2021 FY | 2.63 Million USD | 8.95% |
| 2021 Q4 | 2.63 Million USD | 2.11% |
| 2021 Q3 | 2.58 Million USD | 2.15% |
| 2021 Q2 | 2.52 Million USD | 2.17% |
| 2020 Q4 | 2.42 Million USD | 2.3% |
| 2020 FY | 2.42 Million USD | 9.84% |
| 2020 Q1 | 2.25 Million USD | 2.45% |
| 2020 Q2 | 2.31 Million USD | 2.39% |
| 2020 Q3 | 2.36 Million USD | 2.36% |
| 2019 Q4 | 2.2 Million USD | 2.53% |
| 2019 Q1 | 2.05 Million USD | 2.63% |
| 2019 Q2 | 2.09 Million USD | 1.71% |
| 2019 Q3 | 2.14 Million USD | 2.6% |
| 2019 FY | 2.2 Million USD | 9.82% |
| 2018 FY | 2 Million USD | 3.12% |
| 2018 Q1 | 2 Million USD | 3.01% |
| 2018 Q4 | 2 Million USD | 2.76% |
| 2018 Q3 | 1.95 Million USD | -5.38% |
| 2018 Q2 | 2.06 Million USD | 2.95% |
| 2017 Q3 | 1.94 Million USD | 1.99% |
| 2017 Q1 | 1.82 Million USD | 7.59% |
| 2017 FY | 1.94 Million USD | 14.85% |
| 2017 Q4 | 1.94 Million USD | 0.26% |
| 2017 Q2 | 1.9 Million USD | 4.39% |
| 2016 FY | 1.69 Million USD | 25.35% |
| 2016 Q3 | 1.62 Million USD | -6.58% |
| 2016 Q2 | 1.73 Million USD | 3.24% |
| 2016 Q4 | 1.69 Million USD | 4.57% |
| 2016 Q1 | 1.67 Million USD | 24.29% |
| 2015 FY | 1.35 Million USD | 12.59% |
| 2015 Q4 | 1.35 Million USD | 2.93% |
| 2015 Q1 | 1.24 Million USD | 3.31% |
| 2015 Q2 | 1.24 Million USD | 0.62% |
| 2015 Q3 | 1.31 Million USD | 5.23% |
| 2014 Q3 | 1.1 Million USD | 21.03% |
| 2014 Q2 | 914.69 Thousand USD | -5.57% |
| 2014 FY | 1.2 Million USD | 53.36% |
| 2014 Q4 | 1.2 Million USD | 8.43% |
| 2014 Q1 | 968.64 Thousand USD | 23.76% |
| 2013 FY | 782.69 Thousand USD | 69.58% |
| 2013 Q1 | 506.38 Thousand USD | 9.71% |
| 2013 Q2 | 557.8 Thousand USD | 10.15% |
| 2013 Q3 | 569.53 Thousand USD | 2.1% |
| 2013 Q4 | 782.69 Thousand USD | 37.43% |
| 2012 Q1 | 301.15 Thousand USD | 41.96% |
| 2012 Q3 | 438.43 Thousand USD | 9.3% |
| 2012 Q4 | 461.54 Thousand USD | 5.27% |
| 2012 FY | 461.54 Thousand USD | 117.57% |
| 2012 Q2 | 401.12 Thousand USD | 33.2% |
| 2011 FY | 212.14 Thousand USD | 382.14% |
| 2011 Q4 | 212.14 Thousand USD | 10.54% |
| 2011 Q3 | 191.91 Thousand USD | 28.6% |
| 2011 Q2 | 149.23 Thousand USD | 239.17% |
| 2011 Q1 | 44 Thousand USD | 0.0% |
| 2010 Q2 | 44 Thousand USD | 0.0% |
| 2010 Q4 | 44 Thousand USD | 0.0% |
| 2010 FY | 44 Thousand USD | 0.0% |
| 2010 Q3 | 44 Thousand USD | 0.0% |
| 2010 Q1 | 44 Thousand USD | 0.0% |
| 2009 Q3 | 44 Thousand USD | -99.15% |
| 2009 Q1 | 4.49 Million USD | 13.24% |
| 2009 FY | 44 Thousand USD | -98.89% |
| 2009 Q4 | 44 Thousand USD | 0.0% |
| 2009 Q2 | 5.17 Million USD | 15.19% |
| 2008 Q4 | 3.97 Million USD | 16.76% |
| 2008 Q1 | 1.46 Million USD | 71.0% |
| 2008 Q2 | 2.13 Million USD | 45.5% |
| 2008 Q3 | 3.4 Million USD | 59.67% |
| 2008 FY | 3.97 Million USD | 363.86% |
| 2007 Q3 | 63.21 Thousand USD | 43.68% |
| 2007 Q4 | 856.09 Thousand USD | 1254.19% |
| 2007 Q2 | 44 Thousand USD | 0.0% |
| 2007 FY | 856.09 Thousand USD | 0.0% |
| 2007 Q1 | 44 Thousand USD | 0.0% |
| 2006 FY | - USD | -100.0% |
| 2006 Q1 | 873.67 Thousand USD | 1476.82% |
| 2006 Q2 | 1.89 Million USD | 117.37% |
| 2006 Q3 | 2.92 Million USD | 54.26% |
| 2006 Q4 | - USD | -100.0% |
| 2005 Q4 | 55.4 Thousand USD | -87.62% |
| 2005 Q2 | 447.5 Thousand USD | -1.1% |
| 2005 Q3 | 447.5 Thousand USD | 0.0% |
| 2005 Q1 | 452.5 Thousand USD | 0.0% |
| 2005 FY | 55.4 Thousand USD | -87.76% |
| 2004 FY | 452.5 Thousand USD | 0.0% |
| 2004 Q4 | 452.5 Thousand USD | 0.0% |
| 2003 FY | 452.5 Thousand USD | 0.0% |
| 2003 Q4 | 450 Thousand USD | 0.0% |
| 2002 Q1 | 450 Thousand USD | 12.5% |
| 2002 Q4 | 450 Thousand USD | 0.0% |
| 2002 FY | 452.5 Thousand USD | 13.13% |
| 2001 FY | 400 Thousand USD | -2.44% |
| 2001 Q1 | 450 Thousand USD | 9.76% |
| 2001 Q4 | 400 Thousand USD | -11.11% |
| 2001 Q3 | 450 Thousand USD | 0.0% |
| 2001 Q2 | 450 Thousand USD | 0.0% |
| 2000 Q2 | 410 Thousand USD | -12.77% |
| 2000 Q4 | 410 Thousand USD | 0.0% |
| 2000 Q3 | 410 Thousand USD | 0.0% |
| 2000 Q1 | 470 Thousand USD | -4.08% |
| 2000 FY | 410 Thousand USD | -16.33% |
| 1999 Q2 | 440 Thousand USD | -2.22% |
| 1999 Q1 | 450 Thousand USD | -2.17% |
| 1999 Q3 | 450 Thousand USD | 2.27% |
| 1999 Q4 | 490 Thousand USD | 8.89% |
| 1999 FY | 490 Thousand USD | 6.52% |
| 1998 FY | 460 Thousand USD | -4.17% |
| 1998 Q3 | 540 Thousand USD | -6.9% |
| 1998 Q2 | 580 Thousand USD | 34.88% |
| 1998 Q4 | 460 Thousand USD | -14.81% |
| 1998 Q1 | 430 Thousand USD | -10.42% |
| 1997 Q3 | 410 Thousand USD | -6.82% |
| 1997 Q4 | 480 Thousand USD | 17.07% |
| 1997 Q2 | 440 Thousand USD | 15.79% |
| 1997 Q1 | 380 Thousand USD | 2.7% |
| 1997 FY | 480 Thousand USD | 29.73% |
| 1996 Q3 | 260 Thousand USD | -16.13% |
| 1996 Q1 | 300 Thousand USD | 0.0% |
| 1996 FY | 370 Thousand USD | 0.0% |
| 1996 Q2 | 310 Thousand USD | 3.33% |
| 1996 Q4 | 370 Thousand USD | 42.31% |
| 1995 Q4 | - USD | 0.0% |
| 1995 Q1 | 2 Million USD | 0.0% |
| 1995 Q2 | - USD | -100.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 FY | - USD | -100.0% |
| 1994 FY | 2 Million USD | 0.0% |
| 1994 Q3 | 150 Thousand USD | 0.0% |
| 1994 Q2 | 150 Thousand USD | 0.0% |
| 1994 Q4 | 2 Million USD | 1233.33% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| American Medical Technologies Inc. | 500 Thousand USD | 100.0% |
| Ansell Limited | 855.59 Million USD | 100.0% |
| Ansell Limited | 857.2 Million USD | 100.0% |
| BG Medicine, Inc. | - USD | NaN% |
| Biotage AB (publ) | 22.41 Million USD | 100.0% |
| BioLife Sciences Inc. | - USD | NaN% |
| CB Scientific, Inc. | 20.93 Thousand USD | 100.0% |
| Psykey, Inc. | 1.01 Million USD | 100.0% |
| ConvaTec Group Plc | 1.31 Billion USD | 100.0% |
| ConvaTec Group Plc | 1.31 Billion USD | 100.0% |
| Encision Inc. | 1.33 Million USD | 100.0% |
| Golden Valley Development, Inc | - USD | NaN% |
| Hear AtLast Holdings, Inc. | 2.3 Million USD | 100.0% |
| Innovative MedTech Inc. | 1.87 Million USD | 100.0% |
| LifePoint, Inc. | 446.74 Thousand USD | 100.0% |
| Medite Cancer Diagnostics, Inc. | 5.39 Million USD | 100.0% |
| Paradigm Medical Industries, Inc. | 2.18 Million USD | 100.0% |
| Remedent, Inc. | - USD | NaN% |
| Reflect Scientific, Inc. | 242.64 Thousand USD | 100.0% |
| SmileDirectClub, Inc. | 871.79 Million USD | 100.0% |
| Sector 10, Inc. | 164 Thousand USD | 100.0% |
| Shandong Weigao Group Medical Polymer Company Limited | 674.01 Million USD | 100.0% |
| SheerVision, Inc. | 75 Thousand USD | 100.0% |
| United Health Products, Inc. | 755.98 Thousand USD | 100.0% |
| Vasamed, Inc. | 23.45 Thousand USD | 100.0% |
| Wearable Health Solutions, Inc. | 2.76 Million USD | 100.0% |
| Yubo International Biotech Limited | 790.49 Thousand USD | 100.0% |